Fig. 8: Immunogenicity of SpA* and LukAB RARPR-33 in minipigs. | npj Vaccines

Fig. 8: Immunogenicity of SpA* and LukAB RARPR-33 in minipigs.

From: A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models

Fig. 8

Göttingen minipigs (n = 3) were immunized with 100 µg SpA* + 100 µg LukAB RARPR-33 + AS01B (25 µg MPL and 25 µg QS-21). The control group received antigen formulation buffer. Sera was collected before each immunization and 3 weeks post the third immunization, before challenge. The study is the same as shown in Fig. 7A. Specificity towards A SpA*, B LukAB CC8 or LukAB CC45 was determined by ELISA. IgG EC50 titers are shown. Each point represents a single animal. The geometric mean ± geometric standard deviation of each group is shown. Dotted line indicates limit of detection and is set at 30. Samples below this value are censored to 30. Statistical significance was determined after three immunizations between the animals immunized with SpA* + LukAB RARPR-33 combined with AS01B to the buffer control group and between pre-and post-three immunizations in the vaccinated animals, using a Tobit model, *P < 0.05. AS01B Adjuvant System AS01B, CC clonal complex, EC50 half maximal effective concentration, LukAB leukocidin AB, SpA Staphylococcal protein A.

Back to article page